DeCell signs Domestic and International Agreements for Commercial Production and Sale of DermGEN™

November 9th, 2018

DeCell Technologies Inc. and RegenMed—Ontario’s Premiere Tissue Bank—have signed partnership agreements to manufacture DermGEN™ for both domestic and international sales. RegenMed will both manufacture and distribute DermGEN™ in Canada while also manufacturing DermGEN™ for the International markets. In a separate deal, DeCell has partnered with Impactful Health Solutions (IHS) out of New Jersey, U.S.A., to begin sales of DermGEN™ in markets located in the Middle East. These agreements allow DermGEN™ to enter the healthcare market place so that clinicians can have an advanced, cost effective solution to treat chronic and acute wounds.

For media coverage see Entrevestor’s web-site and the Chronicle Herald’s Business Section

November 6th, 2019

RegenMed Announces Launch of DermGEN™ in Canada in Partnership with

DeCell Technologies

RegenMed—Ontario’s Premiere Tissue Bank located in Thunder Bay, Ontario— and DeCell Technologies Inc. have launched the sale of DermGEN™ for the Canadian marketplace. RegenMed will both manufacture and distribute DermGEN™ in Canada.

January 28th, 2020

DeCell on the Radio

Dr. Paul Gratzer (CSO of DeCell) is interviewed by Sheldon MacLeod on the Sheldon MacLeod Show, News 95.7 Halifax on Jan. 28th, 2020 about using DermGEN™ to treat First Nations people with diabetic foot ulcers:

Other Media Web Links:

1. •  DeCell.Dal-Engineering-Spring2014.pdf
   

2. •Canadian Institutes of Health Research
   

3. •Chronicle Herald
   

4. •Metro News
   

5. •Entrevestor.com
   

6. •Salt Scapes
   

7. •Huffington Post
   

8. •CTV Atlantic News.pdf
   

9. •2013 Biotech Company of the year Nominee
   

10. •2012 BioInnovation Challenge Finalist